Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Shanpar Industries Pvt Ltd

    ShanPar Industries Pvt. Ltd. offers Nutraceuticals, Mineral Fortifiers, Feed Additives & Specialty Chemicals. They specialize in continuous development and introduction of newer

  • No Image
    Sharon Bio Medicine Ltd

    Sharon Bio-Medicine Limited is a Indian Pharmaceutical, Company listed at Bombay Stock Exchange. Over the years it has evolved from being a manufacturer of Intermediates & Activ

  • No Image
    Shasun Pharmaceuticals Ltd

    Shasun is an integrated, global supplier of development and manufacturing services for intermediates, API (Active Pharmaceutical Ingredients) and Formulations to the Pharmaceuti

  • No Image
    Shayona Enterprise Pvt Ltd

    Shayona Enterprise Private Limited is a manufacturer, supplier and exporter of chemical products. Industrial chemicals that they have introduced are feed grade additive, anhydro

  • No Image
    Shilpa Medicare Ltd

    Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in Novem